The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34281470/

RELAY confirmed the clinical relevance of combining EGFR and VEGF(R)-targeting therapies, previously investigated in smaller phase 2-3 trials of erlotinib and bevacizumab. However, the meaningful PFS benefit observed in the ramucirumab + erlotinib arm is counterbalanced by the toxicity profile of ra ...